Form 4: Cardlytics CEO Amit Gupta Reports RSU Vesting and Tax-Related Stock Sale

Cardlytics CEO Amit Gupta reported the vesting of 14,349 restricted stock units and the subsequent sale of 6,725 shares to cover tax withholding obligations.

Summary

• Amit Gupta, Chief Executive Officer and Director of Cardlytics, Inc. (CDLX), reported transactions related to his beneficial ownership.
• On July 1, 2025, 14,349 restricted stock units (RSUs) vested, resulting in the acquisition of an equal number of common stock shares.
• Following this vesting, direct beneficial ownership of common stock increased to 385,429 shares.
• On July 2, 2025, 6,725 shares of common stock were sold at a weighted average price of $1.7826 per share.
• The sale was executed solely to satisfy tax withholding obligations arising from the RSU vesting, with shares sold in a price range of $1.66 to $1.8451.
• After the sale, direct beneficial ownership of common stock stands at 378,704 shares.
• 43,049 restricted stock units remain beneficially owned.
• The original RSU award was for 114,796 shares, scheduled to vest in eight equal installments on July 1, 2024, October 1, 2024, January 1, 2025, April 1, 2025, July 1, 2025, October 1, 2025, January 1, 2026, and April 1, 2026, contingent on continued employment.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The RSU vesting indicates continued executive incentive alignment, and the sale was for tax purposes, not a discretionary sale, which is generally viewed less negatively. However, the low sale price is a minor negative.

Positives

• Vesting of restricted stock units indicates continued long-term incentive alignment between management and shareholders.
• The sale of shares was solely for tax withholding purposes, which is a routine event and generally viewed more favorably than discretionary sales.

Negatives

• A portion of shares were sold, reducing direct ownership, although the sale was for tax purposes.
• The weighted average sale price of $1.7826 per share reflects the current market valuation of the stock.

Future Outlook

The document indicates future RSU vesting dates through April 1, 2026, contingent on the CEO's continued employment, suggesting ongoing alignment of executive incentives with long-term company performance.

Industry Context

This Form 4 is a routine insider transaction report and does not provide specific industry context. It reflects standard executive compensation practices involving equity awards common across various industries.

Comparison to Industry Standards

• Insider sales solely for tax withholding are a common and standard practice for executives receiving equity compensation across industries.
• The specific share price and volume are company-specific and are not directly comparable to industry benchmarks without broader context of Cardlytics' market performance and peer valuations.

Stakeholder Impact

• Shareholders: The report provides transparency on executive stock ownership and compensation, which can influence investor confidence. The sale for tax purposes is a routine event and typically has minimal direct impact on share price unless the volume is unusually large or signals a lack of confidence.
• Employees: The RSU vesting schedule indicates ongoing executive retention and incentive programs.

Next Steps

• Future vesting of remaining 43,049 Restricted Stock Units on scheduled dates through April 1, 2026, contingent on continued employment.

Key Dates

Keywords

Cardlytics, CDLX, Amit Gupta, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Executive Compensation, Beneficial Ownership